In contrast to CEACAM5 and CXCL17, two markers demonstrated lower levels in the plasma of cancer patients: VEGFR2 acts as a cell-surface receptor for vascular endothelial growth factors (VEGFA, VEGFC and VEGFD), and is involved in angiogenesis in both physiological and pathological conditions. Here, KDR is linked to cancer.